{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:31:11Z","timestamp":1784370671030,"version":"3.55.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10147-023-02307-z","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T17:02:34Z","timestamp":1678035754000},"page":"625-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-1551","authenticated-orcid":false,"given":"Takeshi","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"key":"2307_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR et al (2019) Bevacizumab-associated glomerular microangiopathy. Modern Pathol 32:684\u2013700","journal-title":"Modern Pathol"},{"key":"2307_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763\u2013773","journal-title":"J Natl Cancer Inst"},{"key":"2307_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435\u2013446","journal-title":"J Am Soc Nephrol"},{"key":"2307_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","volume":"9","author":"S Gupta","year":"2021","unstructured":"Gupta S, Short SAP, Sise ME et al (2021) Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9:e003467","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2307_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.34067\/KID.0000852019","volume":"360","author":"S Gupta","year":"2020","unstructured":"Gupta S, Cortazar FB, Riella LV et al (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney 360(1):130\u2013140","journal-title":"Kidney"},{"key":"2307_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4081\/oncol.2019.455","volume":"13","author":"RK Paluri","year":"2019","unstructured":"Paluri RK, Sonpavde G, Morgan C et al (2019) Renal toxicity with mammalian target of rapamycin inhibitors: a meta-analysis of randomized clinical trials. Oncol Rev 13:455","journal-title":"Oncol Rev"},{"key":"2307_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","volume":"17","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, Gambacorti-Passerini C, Kim DW et al (2017) Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk 17:684-695.e686","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2307_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507\u2013516","journal-title":"N Engl J Med"},{"key":"2307_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.28478","volume":"120","author":"EM Brosnan","year":"2014","unstructured":"Brosnan EM, Weickhardt AJ, Lu X et al (2014) Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 120:664\u2013674","journal-title":"Cancer"},{"key":"2307_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1634\/theoncologist.2014-0216","volume":"19","author":"SJ Klempner","year":"2014","unstructured":"Klempner SJ, Aubin G, Dash A et al (2014) Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 19:1008\u20131010","journal-title":"Oncologist"},{"key":"2307_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ckj\/sfv149","volume":"9","author":"R Wanchoo","year":"2016","unstructured":"Wanchoo R, Jhaveri KD, Deray G et al (2016) Renal effects of BRAF inhibitors: a systematic review by the cancer and the kidney international network. Clin Kidney J 9:245\u2013251","journal-title":"Clin Kidney J"},{"key":"2307_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","volume":"1","author":"KD Jhaveri","year":"2015","unstructured":"Jhaveri KD, Sakhiya V, Fishbane S (2015) Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol 1:1133\u20131134","journal-title":"JAMA Oncol"},{"key":"2307_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/cpt.1296","volume":"105","author":"JC Chappell","year":"2019","unstructured":"Chappell JC, Turner PK, Pak YA et al (2019) Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. Clin Pharmacol Ther 105:1187\u20131195","journal-title":"Clin Pharmacol Ther"},{"key":"2307_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","volume":"7","author":"S Gupta","year":"2022","unstructured":"Gupta S, Caza T, Herrmann SM et al (2022) Clinicopathologic features of acute kidney injury associated with CDK4\/6 inhibitors. Kidney Int Rep 7:618\u2013623","journal-title":"Kidney Int Rep"},{"key":"2307_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12885-016-2271-8","volume":"16","author":"K Sato","year":"2016","unstructured":"Sato K, Watanabe S, Ohtsubo A et al (2016) Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16:222","journal-title":"BMC Cancer"},{"key":"2307_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/02841868909111182","volume":"28","author":"M Adams","year":"1989","unstructured":"Adams M, Kerby IJ, Rocker I et al (1989) A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol 28:57\u201360","journal-title":"Acta Oncol"},{"key":"2307_CR17","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/jnci\/81.19.1464","volume":"81","author":"C Mangioni","year":"1989","unstructured":"Mangioni C, Bolis G, Pecorelli S et al (1989) Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81:1464\u20131471","journal-title":"J Natl Cancer Inst"},{"key":"2307_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF et al (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609\u2013619","journal-title":"Oncologist"},{"key":"2307_CR19","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ckj\/sfz183","volume":"13","author":"G Ensergueix","year":"2020","unstructured":"Ensergueix G, Pallet N, Joly D et al (2020) Ifosfamide nephrotoxicity in adult patients. Clin Kidney J 13:660\u2013665","journal-title":"Clin Kidney J"},{"key":"2307_CR20","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1200\/JCO.2008.17.5257","volume":"27","author":"O Oberlin","year":"2009","unstructured":"Oberlin O, Fawaz O, Rey A et al (2009) Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol 27:5350\u20135355","journal-title":"J Clin Oncol"},{"key":"2307_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/pbc.20858","volume":"48","author":"W St\u00f6hr","year":"2007","unstructured":"St\u00f6hr W, Paulides M, Bielack S et al (2007) Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 48:447\u2013452","journal-title":"Pediatr Blood Cancer"},{"key":"2307_CR22","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/adc.65.7.732","volume":"65","author":"R Skinner","year":"1990","unstructured":"Skinner R, Pearson AD, Price L et al (1990) Nephrotoxicity after ifosfamide. Arch Dis Child 65:732\u2013738","journal-title":"Arch Dis Child"},{"key":"2307_CR23","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1054\/bjoc.2000.1214","volume":"82","author":"R Skinner","year":"2000","unstructured":"Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. United Kingdom Children\u2019s Cancer Study Group. Br J Cancer 82:1636\u20131645","journal-title":"Br J Cancer"},{"key":"2307_CR24","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/1097-0142(19951215)76:12<2557::AID-CNCR2820761223>3.0.CO;2-9","volume":"76","author":"PT Ho","year":"1995","unstructured":"Ho PT, Zimmerman K, Wexler LH et al (1995) A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 76:2557\u20132564","journal-title":"Cancer"},{"key":"2307_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00467-007-0689-6","volume":"23","author":"Z Yaseen","year":"2008","unstructured":"Yaseen Z, Michoudet C, Baverel G et al (2008) In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro. Pediatr Nephrol 23:611\u2013618","journal-title":"Pediatr Nephrol"},{"key":"2307_CR26","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/1097-0142(197511)36:5<1572::AID-CNCR2820360506>3.0.CO;2-T","volume":"36","author":"HJ Lawrence","year":"1975","unstructured":"Lawrence HJ, Simone J, Aur RJ (1975) Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. Cancer 36:1572\u20131576","journal-title":"Cancer"},{"key":"2307_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/jnci\/80.8.556","volume":"80","author":"M Zalupski","year":"1988","unstructured":"Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80:556\u2013566","journal-title":"J Natl Cancer Inst"},{"key":"2307_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0305-7372(85)90011-8","volume":"12","author":"WP Brade","year":"1985","unstructured":"Brade WP, Herdrich K, Varini M (1985) Ifosfamide\u2013pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1\u201347","journal-title":"Cancer Treat Rev"},{"key":"2307_CR29","doi-asserted-by":"publisher","first-page":"779881","DOI":"10.3389\/fimmu.2021.779881","volume":"12","author":"M Miyata","year":"2021","unstructured":"Miyata M, Ichikawa K, Matsuki E et al (2021) Recent advances of acute kidney injury in hematopoietic cell transplantation. Front Immunol 12:779881","journal-title":"Front Immunol"},{"key":"2307_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hon.2759","volume":"38","author":"I Amitai","year":"2020","unstructured":"Amitai I, Rozovski U, El-Saleh R et al (2020) Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol 38:584\u2013588","journal-title":"Hematol Oncol"},{"key":"2307_CR31","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.20255","volume":"100","author":"BC Widemann","year":"2004","unstructured":"Widemann BC, Balis FM, Kempf-Bielack B et al (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100:2222\u20132232","journal-title":"Cancer"},{"key":"2307_CR32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","volume":"1","author":"HT Abelson","year":"1983","unstructured":"Abelson HT, Fosburg MT, Beardsley GP et al (1983) Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1:208\u2013216","journal-title":"J Clin Oncol"},{"key":"2307_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694\u2013703","journal-title":"Oncologist"},{"key":"2307_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1385\/MO:23:3:419","volume":"23","author":"V Vootukuru","year":"2006","unstructured":"Vootukuru V, Liew YP, Nally JV Jr (2006) Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 23:419\u2013422","journal-title":"Med Oncol"},{"key":"2307_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15171\/jnp.2017.07","volume":"6","author":"T Zattera","year":"2017","unstructured":"Zattera T, Londrino F, Trezzi M et al (2017) Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J Nephropathol 6:43\u201348","journal-title":"J Nephropathol"},{"key":"2307_CR36","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3109\/0886022X.2010.501930","volume":"32","author":"A Stavroulopoulos","year":"2010","unstructured":"Stavroulopoulos A, Nakopoulou L, Xydakis AM et al (2010) Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 32:1000\u20131004","journal-title":"Ren Fail"},{"key":"2307_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","volume":"146","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Boosman RJ, van de Bruinhorst H et al (2020) Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 146:30\u201335","journal-title":"Lung Cancer"},{"key":"2307_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171066","volume":"12","author":"H Kawazoe","year":"2017","unstructured":"Kawazoe H, Yano A, Ishida Y et al (2017) Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: a retrospective cohort study. PLoS ONE 12:e0171066","journal-title":"PLoS ONE"},{"key":"2307_CR39","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","volume":"8","author":"M Zupancic","year":"2007","unstructured":"Zupancic M, Shah PC, Shah-Khan F et al (2007) Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 8:634\u2013641","journal-title":"Lancet Oncol"},{"key":"2307_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","volume":"22","author":"M Grall","year":"2021","unstructured":"Grall M, Daviet F, Chiche NJ et al (2021) Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrol 22:267","journal-title":"BMC Nephrol"},{"key":"2307_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clcc.2011.03.012","volume":"10","author":"R El-Ghazal","year":"2011","unstructured":"El-Ghazal R, Podoltsev N, Marks P et al (2011) Mitomycin\u2013C-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer 10:142\u2013145","journal-title":"Clin Colorectal Cancer"},{"key":"2307_CR42","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147\u20131154","journal-title":"Lancet"},{"key":"2307_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.ajkd.2011.08.029","volume":"59","author":"SM Doshi","year":"2012","unstructured":"Doshi SM, Shah P, Lei X et al (2012) Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 59:222\u2013228","journal-title":"Am J Kidney Dis"},{"key":"2307_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF01788840","volume":"4","author":"T Berghmans","year":"1996","unstructured":"Berghmans T (1996) Hyponatremia related to medical anticancer treatment. Support Care Cancer 4:341\u2013350","journal-title":"Support Care Cancer"},{"key":"2307_CR45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","volume":"80","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Caroen S, Oronsky A et al (2017) Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol 80:895\u2013907","journal-title":"Cancer Chemother Pharmacol"},{"key":"2307_CR46","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","volume":"36","author":"H Seethapathy","year":"2021","unstructured":"Seethapathy H, Rusibamayila N, Chute DF et al (2021) Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant 36:2241\u20132247","journal-title":"Nephrol Dial Transplant"},{"key":"2307_CR47","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/cam4.805","volume":"6","author":"RJ Gralla","year":"2017","unstructured":"Gralla RJ, Ahmad F, Blais JD et al (2017) Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Cancer Med 6:723\u2013729","journal-title":"Cancer Med"},{"key":"2307_CR48","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671\u2013684","journal-title":"Lancet Oncol"},{"key":"2307_CR49","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/ckj\/sfab078","volume":"14","author":"S Adhikari","year":"2021","unstructured":"Adhikari S, Mamlouk O, Rondon-Berrios H et al (2021) Hypophosphatemia in cancer patients. Clin Kidney J 14:2304\u20132315","journal-title":"Clin Kidney J"},{"key":"2307_CR50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood.V57.1.182.182","volume":"57","author":"BA Peterson","year":"1981","unstructured":"Peterson BA, Collins AJ, Vogelzang NJ et al (1981) 5-azacytidine and renal tubular dysfunction. Blood 57:182\u2013185","journal-title":"Blood"},{"key":"2307_CR51","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006\u20132013","journal-title":"N Engl J Med"},{"key":"2307_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0305-7372(85)90017-9","volume":"12","author":"BJ Foster","year":"1985","unstructured":"Foster BJ, Clagett-Carr K, Leyland-Jones B et al (1985) Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 12:43\u201349","journal-title":"Cancer Treat Rev"},{"key":"2307_CR53","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1007\/s13277-014-2983-9","volume":"36","author":"Q Wang","year":"2015","unstructured":"Wang Q, Qi Y, Zhang D et al (2015) Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumor Biology 36:3471\u20133482","journal-title":"Tumor Biology"},{"issue":"2","key":"2307_CR54","doi-asserted-by":"publisher","first-page":"154","DOI":"10.34067\/KID.0005622020","volume":"360","author":"BT Workeneh","year":"2021","unstructured":"Workeneh BT, Uppal NN, Jhaveri KD et al (2021) Hypomagnesemia in the cancer patient. Kidney 360(2):154","journal-title":"Kidney"},{"key":"2307_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s13730-019-00437-w","volume":"9","author":"A Asai","year":"2020","unstructured":"Asai A, Katsuno T, Yamaguchi M et al (2020) Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor. CEN Case Rep 9:114\u2013121","journal-title":"CEN Case Rep"},{"key":"2307_CR56","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s12032-009-9263-3","volume":"27","author":"A Ulusakarya","year":"2010","unstructured":"Ulusakarya A, Misra S, Haydar M et al (2010) Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol 27:1425\u20131426","journal-title":"Med Oncol"},{"key":"2307_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4172\/2376-0311.1000106","volume":"2","author":"F Mahmood","year":"2014","unstructured":"Mahmood F, Matar M, Davis A (2014) Renal failure and hypocalcaemia secondary to cabazitaxel treatment for prostate cancer: a rare but potentially lethal side effect. J Clin Diagn Res 2:106\u2013108","journal-title":"J Clin Diagn Res"},{"key":"2307_CR58","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000355753","volume":"38","author":"F Fabrizi","year":"2013","unstructured":"Fabrizi F, Aghemo A, Fogazzi GB et al (2013) Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res 38:52\u201360","journal-title":"Kidney Blood Press Res"},{"key":"2307_CR59","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/annonc\/mdt233","volume":"24","author":"H Izzedine","year":"2013","unstructured":"Izzedine H, Escudier B, Rouvier P et al (2013) Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 24:2421\u20132425","journal-title":"Ann Oncol"},{"key":"2307_CR60","first-page":"2889","volume":"36","author":"N Kreiniz","year":"2016","unstructured":"Kreiniz N, Khateeb ALI, Gino-Moor S et al (2016) Acute renal failure associated with lenalidomide treatment in multiple myeloma: a rare occurrence? Anticancer Res 36:2889","journal-title":"Anticancer Res"},{"key":"2307_CR61","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1634\/theoncologist.2010-0070","volume":"15","author":"EJ Lipson","year":"2010","unstructured":"Lipson EJ, Huff CA, Holanda DG et al (2010) Lenalidomide-induced acute interstitial nephritis. Oncologist 15:961\u2013964","journal-title":"Oncologist"},{"key":"2307_CR62","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","volume":"123","author":"MA Sanz","year":"2014","unstructured":"Sanz MA, Montesinos P (2014) How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123:2777\u20132782","journal-title":"Blood"},{"key":"2307_CR63","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1093\/ndt\/gfm199","volume":"22","author":"H Izzedine","year":"2007","unstructured":"Izzedine H, Brocheriou I, Rixe O et al (2007) Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 22:2411\u20132411","journal-title":"Nephrol Dial Transplant"},{"key":"2307_CR64","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ndt\/gfn625","volume":"24","author":"SK Winn","year":"2009","unstructured":"Winn SK, Ellis S, Savage P et al (2009) Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 24:673\u2013675","journal-title":"Nephrol Dial Transplant"},{"key":"2307_CR65","first-page":"6328204","volume":"2017","author":"I Azar","year":"2017","unstructured":"Azar I, Esfandiarifard S, Sinai P et al (2017) Sunitinib-induced acute interstitial nephritis in a thrombocytopenic renal cell cancer patient. Case Rep Oncol Med 2017:6328204","journal-title":"Case Rep Oncol Med"},{"key":"2307_CR66","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/cncr.28709","volume":"120","author":"V Launay-Vacher","year":"2014","unstructured":"Launay-Vacher V, Zimner-Rapuch S, Poulalhon N et al (2014) Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 120:2158\u20132163","journal-title":"Cancer"},{"key":"2307_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","volume":"101","author":"AM Jackson","year":"1984","unstructured":"Jackson AM, Rose BD, Graff LG et al (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101:41\u201344","journal-title":"Ann Intern Med"},{"key":"2307_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12882-021-02386-y","volume":"22","author":"M Nishikubo","year":"2021","unstructured":"Nishikubo M, Shimomura Y, Hiramoto N et al (2021) Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. BMC Nephrol 22:175","journal-title":"BMC Nephrol"},{"key":"2307_CR69","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","volume":"17","author":"JA Blake-Haskins","year":"2011","unstructured":"Blake-Haskins JA, Lechleider RJ, Kreitman RJ (2011) Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17:5858\u20135866","journal-title":"Clin Cancer Res"},{"key":"2307_CR70","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","volume":"128","author":"D Kavanagh","year":"2016","unstructured":"Kavanagh D, McGlasson S, Jury A et al (2016) Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 128:2824\u20132833","journal-title":"Blood"},{"key":"2307_CR71","doi-asserted-by":"publisher","first-page":"8599","DOI":"10.1007\/s00520-022-06935-5","volume":"30","author":"C Font","year":"2022","unstructured":"Font C, de Herreros MG, Tsoukalas N et al (2022) The MHSG: thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. Support Care Cancer 30:8599\u20138609","journal-title":"Support Care Cancer"},{"key":"2307_CR72","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/diagnostics11040640","volume":"11","author":"M Van Wynsberghe","year":"2021","unstructured":"Van Wynsberghe M, Flejeo J, Sakhi H et al (2021) Nephrotoxicity of anti-angiogenic therapies. Diagnostics 11:640","journal-title":"Diagnostics"},{"key":"2307_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090135","volume":"9","author":"Z-F Zhang","year":"2014","unstructured":"Zhang Z-F, Wang T, Liu L-H et al (2014) Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS ONE 9:e90135","journal-title":"PLoS ONE"},{"key":"2307_CR74","doi-asserted-by":"crossref","unstructured":"Arai H, Yamamoto S, Matsubara T, Miyake T, Tochio A, Mii A, Shimizu A, Minamiguchi S, Muso E, Yanagita M. 2022. Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib: A Case Report. Internal Medicine, advpub. https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_1283-22\/_article","DOI":"10.2169\/internalmedicine.1283-22"},{"key":"2307_CR75","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1200\/PO.20.00279","volume":"1","author":"CE McCoach","year":"2021","unstructured":"McCoach CE, Yu A, Gandara DR et al (2021) Phase I\/II study of capmatinib plus erlotinib in patients with MET-positive non-small-cell lung cancer. JCO Precis Oncol 1:177\u2013190","journal-title":"JCO Precis Oncol"},{"key":"2307_CR76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13730-014-0135-0","volume":"4","author":"T Kaneko","year":"2015","unstructured":"Kaneko T, Shimizu A, Aoki M et al (2015) A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Reports 4:31\u201337","journal-title":"CEN Case Reports"},{"key":"2307_CR77","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2169\/internalmedicine.54.3661","volume":"54","author":"K Maruyama","year":"2015","unstructured":"Maruyama K, Chinda J, Kuroshima T et al (2015) Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med 54:823\u2013826","journal-title":"Intern Med"},{"key":"2307_CR78","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"H Akamatsu","year":"2021","unstructured":"Akamatsu H, Toi Y, Hayashi H et al (2021) Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M\u2013mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: west Japan oncology group 8715l phase 2 randomized clinical trial. JAMA Oncol 7:386\u2013394","journal-title":"JAMA Oncol"},{"key":"2307_CR79","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1038\/s41467-019-09936-x","volume":"10","author":"RC Calizo","year":"2019","unstructured":"Calizo RC, Bhattacharya S, van Hasselt JGC et al (2019) Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun 10:2061","journal-title":"Nat Commun"},{"key":"2307_CR80","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1751-7176.2008.07758.x","volume":"10","author":"E Grossman","year":"2008","unstructured":"Grossman E, Messerli FH (2008) Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 10:556\u2013566","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2307_CR81","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/20009666.2018.1478563","volume":"8","author":"M Hamid","year":"2018","unstructured":"Hamid M, Ghani A, Micaily I et al (2018) Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. J Community Hosp Intern Med Perspect 8:130\u2013133","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2307_CR82","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1365-2125.2012.04417.x","volume":"75","author":"WX Qi","year":"2013","unstructured":"Qi WX, Shen Z, Lin F et al (2013) Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 75:919\u2013930","journal-title":"Br J Clin Pharmacol"},{"key":"2307_CR83","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","volume":"5","author":"TE Stinchcombe","year":"2019","unstructured":"Stinchcombe TE, Janne PA, Wang X et al (2019) Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 5:1448\u20131455","journal-title":"JAMA Oncol"},{"key":"2307_CR84","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12185-017-2238-9","volume":"106","author":"A Tojo","year":"2017","unstructured":"Tojo A, Kyo T, Yamamoto K et al (2017) Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study. Int J Hematol 106:385\u2013397","journal-title":"Int J Hematol"},{"key":"2307_CR85","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108\u20132121","journal-title":"J Clin Oncol"},{"key":"2307_CR86","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT et al (2018) Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol 4:e174519","journal-title":"JAMA Oncol"},{"key":"2307_CR87","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A et al (2019) Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 134:1919\u20131928","journal-title":"Blood"},{"key":"2307_CR88","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/annonc\/mdu132","volume":"25","author":"T Grellety","year":"2014","unstructured":"Grellety T, Hou\u00e9d\u00e9 N, Hoepffner JL et al (2014) Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome? Ann Oncol 25:1248\u20131249","journal-title":"Ann Oncol"},{"key":"2307_CR89","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.23788","volume":"89","author":"C Gambacorti-Passerini","year":"2014","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH et al (2014) Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 89:947\u2013953","journal-title":"Am J Hematol"},{"key":"2307_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omy009","author":"K Nagai","year":"2018","unstructured":"Nagai K, Ono H, Matsuura M et al (2018) Progressive renal insufficiency related to ALK inhibitor, alectinib. Oxf Med Case Reports. https:\/\/doi.org\/10.1093\/omcr\/omy009","journal-title":"Oxf Med Case Reports"},{"key":"2307_CR91","unstructured":"Full prescribing information for ROZLYTREK, FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC; https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc. Accessed Feb 2022"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02307-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02307-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02307-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T08:24:11Z","timestamp":1681979051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02307-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02307-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]},"assertion":[{"value":"27 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MY receives research grants from Mitsubishi Tanabe Pharma and Boehringer Ingelheim. H Yokoi has received research grants from Mitsubishi Tanabe Pharma, and honoraria from AstraZeneca and Mitsubishi Tanabe Pharma. The other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}